Works matching AU Liu, Wenyu


Results: 175
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    35
    36
    37
    38
    39
    40

    TUXEDO: a phase I/II trial of cetuximab with chemoradiotherapy in muscle‐invasive bladder cancer.

    Published in:
    BJU International, 2023, v. 131, n. 1, p. 63, doi. 10.1111/bju.15864
    By:
    • James, Nicholas D.;
    • Liu, Wenyu;
    • Pirrie, Sarah;
    • Kaur, Baljit;
    • Hendron, Carey;
    • Ford, Daniel;
    • Zarkar, Anjali;
    • Viney, Richard;
    • Southgate, Elizabeth;
    • Desai, Amisha;
    • Hussain, Syed A.;
    • Barber, Jim;
    • Syndikus, Isabel;
    • Malik, Zafar;
    • Eswar, Chinnamani;
    • Mangar, Stephen;
    • Money‐Kyrle, Julian;
    • Lydon, Anna;
    • Van Der Voet, Johannes;
    • James, Nicholas
    Publication type:
    Article
    41
    42
    43
    44
    45
    46

    Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 6, p. 446, doi. 10.1016/j.clml.2023.02.009
    By:
    • Fu, Weijun;
    • Bang, Soo-Mee;
    • Huang, Honghui;
    • Kim, Kihyun;
    • Li, Wei;
    • An, Gang;
    • Lee, Je-Jung;
    • Cai, Zhen;
    • Jin, Jie;
    • Wang, Yafei;
    • Lin, Tung-Liang;
    • Chim, Chor Sang;
    • Qi, Ming;
    • Wang, Jianping;
    • Lu, Xiaolin;
    • Song, Yang;
    • Jia, Bin;
    • Yang, Xue;
    • Liu, Wenyu;
    • Zhou, Tianyuan
    Publication type:
    Article
    47
    48

    P-163: Efficacy and safety of Daratumumab, Bortezomib, Melphalan, and Prednisone (D-VMP) versus Bortezomib, Melphalan, and Prednisone (VMP) in Chinese patients with newly diagnosed Multiple Myeloma: OCTANS.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S125, doi. 10.1016/S2152-2650(21)02290-4
    By:
    • Weijun Fu;
    • Honghui Huang;
    • Wei Li;
    • Gang An;
    • Zhen Cai;
    • Jie Jin;
    • Yafei Wang;
    • Chor Sang Chim;
    • Ming Qi;
    • Jianping Wang;
    • Yang Song;
    • Bin Jia;
    • Xue Yang;
    • Wenyu Liu;
    • Yunan Li;
    • Renyi Zhang;
    • Jian Hou;
    • Jianxiang Wang
    Publication type:
    Article
    49

    Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, n. 9, p. e699, doi. 10.1016/j.clml.2021.04.012
    By:
    • Lu, Jin;
    • Fu, Weijun;
    • Li, Wei;
    • Hu, Jianda;
    • An, Gang;
    • Wang, Yafei;
    • Fu, Chengcheng;
    • Chen, Lijuan;
    • Jin, Jie;
    • Cen, Xinan;
    • Ge, Zheng;
    • Cai, Zhen;
    • Niu, Ting;
    • Qi, Ming;
    • Sun, Steven;
    • Gai, Xue;
    • Liu, Weiping;
    • Liu, Wenyu;
    • Yang, Xue;
    • Huang, Xiaojun
    Publication type:
    Article
    50